Data Sources for the Population Pharmacokinetic Model of Semaglutide
The population pharmacokinetic model for semaglutide used data generated from five of the phase III SUSTAIN trials; these were SUSTAIN 1, 2, 3, 6, and SUSTAIN-Japan [
13‐
15,
19,
20]. The design of these trials is summarized in Table
1.
Table 1
Characteristics of trials included in the population PK analysis
Blinding | Double blind | Double blind | Open label | Double blind | Open label |
Comparator | Placebo | Sitagliptin 100 mg | Exenatide ER 2.0 mg | Placebo | Additional OAD |
Semaglutide maintenance dose | 0.5, 1.0 mg | 0.5, 1.0 mg | 1.0 mg | 0.5, 1.0 mg | 0.5, 1.0 mg |
Randomization | 2:2:1:1a | 2:2:1:1b | 1:1 | 1:1:1:1a | 2:2:1c |
Planned number subjects randomized | 390 | 1200 | 798 | 3260 | 595 |
Planned number subjects randomized to semaglutide | 260 | 800 | 399 | 1630 | 480 |
Treatment duration | 30 weeks | 56 weeks | 56 weeks | 104 weeks | 56 weeks |
Background medication | None | 1–2 OADs (either MET, PIO, ROSI, or a combination of either MET/PIO or MET/ROSI | 1–2 OADs (MET and/or TZD and SU) | 0–2 OADs, basal or premixed insulins ± 0-2 OADs. Background medication was allowed to change during the trial | 0–1 OAD (of SU, glinide, α-GI or TZD) |
Clinicaltrials.gov identifier | NCT02054897 | NCT01930188 | NCT01885208 | NCT01720446 | NCT02207374 |
The trials included in the model were all global trials, with the exception of the Japanese trial. Male and female subjects diagnosed with T2DM were included, with an age ≥ 18 years (Japanese patients ≥ 20 years). For all trials, subjects had a minimum HbA
1c of 7.0%, and there were no restrictions on body weight or body mass index (BMI). With the exception of SUSTAIN 6, inclusion and exclusion criteria were overall similar across all trials. Concomitant oral anti-diabetic drugs (OADs) were allowed for all trials (except in SUSTAIN 1, which was a monotherapy trial). Subjects enrolled in SUSTAIN 6 were also allowed basal or pre-mix insulin. SUSTAIN 6 was a pre-approval cardiovascular and other long-term outcomes trial with an enriched CVD population (aged ≥ 50 years with clinical evidence of CVD or aged ≥ 60 years with cardiovascular risk factors). Subjects with normal or mildly impaired renal function [defined as estimated glomerular filtration rate (eGFR) ≥ 90 ml/min/1.73 m
2 for normal function or eGFR of 60–89 ml/min/1.73 m
2 for mildly impaired function] were enrolled in all trials. SUSTAIN 1, SUSTAIN 6, and SUSTAIN-Japan also included subjects with moderate renal impairment (eGFR of 30–59 ml/min/1.73 m
2). In SUSTAIN 6, the pharmacokinetic (PK) properties of semaglutide were assessed in subjects with severe impaired renal function (eGFR < 30 ml/min/1.73 m
2) as well as subjects with less severe renal impairment or normal renal function. For more information on inclusion and exclusion criteria in the individual trials, see the trial publications [
13‐
15,
19,
20].
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments and Good Clinical Practice [
21,
22]. The trial protocols were approved by independent ethics committees and/or institutional review boards. All subjects provided written informed consent before initiation of any trial-related activities.
Subjects included in the population pharmacokinetic analysis were randomized to a maintenance dose of either 0.5 mg or 1.0 mg semaglutide once weekly. SUSTAIN 3 used only the 1.0 mg maintenance dose for the semaglutide treatment arm (Table
1). In all trials, subjects taking semaglutide followed a dose-escalation regimen with the aim of minimizing gastrointestinal adverse events common to the class of GLP-1RAs [
23]. Subjects started with 4 weeks of treatment with 0.25 mg semaglutide once weekly before escalating to 0.5 mg semaglutide once weekly. Subjects randomized to the 1.0 mg semaglutide treatment arm would escalate to the 1.0 mg dose after 4 weeks of 0.5 mg semaglutide, remaining on this dose for the duration of the trial. The subcutaneous injections should be administered on the same day of each week, and subjects providing blood samples to be used in the population pharmacokinetic model were encouraged to inject in the same area of the body throughout the trial.
Blood samples for the PK measurement were drawn at approximately 4, 8, 16, and 30 weeks after the first dose in all trials, and all except SUSTAIN 1 included a sample during week 56. SUSTAIN 6 had additional samples taken during week 2 and at end of treatment (minimum 104 weeks after first dose). There were no restrictions on the timing of the blood sample relative to dosing.
Subjects recorded the date, time, and injection site for the initial dose and the two doses prior to each blood sampling in a diary. This information was transferred, along with the date and time of blood sampling to an electronic case report form at each sampling visit.
Subjects exposed to at least one dose of semaglutide and with at least one valid PK measurement were included in the data set, which included dosing information for all recorded injections, semaglutide concentrations, and covariate values. Records with concentration values missing or below the lower limit of quantification, other dosing deviations, or missing information were excluded from the analysis. Dosing deviations were defined as missing injections or if the last two injections prior to blood sampling were administered less than 120 h apart. Missing information was defined as incomplete diary information for 2 weeks before blood sampling.
Population Pharmacokinetic Model
A pre-specified full model approach was used for the population PK analysis, including a base model without covariates and a full model with all covariates included [
25,
26].
The base model was a one-compartment model with first-order absorption and elimination. This model has been shown to provide an adequate description of the PK of semaglutide (Novo Nordisk, data on file). The model was parameterized for semaglutide in terms of ka (absorption rate constant), CL/F (apparent clearance), and V/F (apparent volume of distribution). The semaglutide absorption rate constant (ka) was set to 0.0286 h−1 based on data from clinical pharmacology trials with richly sampled PK profiles (Novo Nordisk, data on file). The model was estimated on un-transformed concentration values, and a proportional error model was used to describe the residual variability. Models were estimated using first-order conditional estimation with interaction (FOCE + I).
The full model was used for estimating the potential effects of individual covariates on semaglutide plasma exposure in terms of clearance. The average semaglutide concentration (
Cavg) during the dosing interval was
$$ C_{\text{avg}} = \frac{{{\text{AUC}}_{\text{ss,0 - 168h}} }}{168\;h}\; $$
The area under the curve at steady state (AUC
ss,0–168h) was calculated by
$$ {\text{AUC}}_{\text{ss,0 - 168h}} = \frac{\text{Dose}}{{{\text{CL/}}F}}, $$
where ‘dose’ was the relevant maintenance dose for the subject, and CL/
F was the individually estimated apparent clearance from the population pharmacokinetic model.
The covariates were included to investigate exposures in relevant sub-populations [
2,
27,
28] and the dosing characteristics of semaglutide. Covariates were categorical, with the exception of body weight. Age was categorized into three groups, < 64, 65–74, or ≥ 75 years old at baseline. Renal impairment groups were categorized [by estimated glomerular filtration rate (eGFR)] as normal function (eGFR ≥ 90 ml/min/1.73 m
2), mild (eGFR = 60–89 ml/min/1.73 m
2), moderate (eGFR = 30–59 ml/min/1.73 m
2), or severe (eGFR < 30 ml/min/1.73 m
2) renal impairment. Baseline body weight was included as a continuous covariate. For semaglutide, there are two maintenance doses (0.5 and 1.0 mg), which were included as covariates to assess the dose dependency of semaglutide exposure. The injection site (abdomen, thigh or upper arm) was also included as a covariate, whereby the most frequently used injection site for an individual patient was used as the covariate value. Additionally, race and ethnicity were included as covariates.
The reference subject profile was defined as a non-Hispanic or non-Latino, white female < 65 years old, with a body weight of 85 kg (pre-specified, representing the expected approximate median body weight of the study population) with normal renal function and dosed in the abdomen with semaglutide 1.0 mg once weekly.
The model was parameterized as:
$$ \begin{aligned} {\text{CL}}_{i} /F = {\text{CL}}_{\text{typ}} \cdot E_{\text{dose}} \cdot E_{\text{weight}} \cdot E_{\text{sex}} \cdot E_{\text{age}} \cdot E_{\text{GFR}} \cdot E_{\text{race}} \cdot E_{\text{ethnicity}} \cdot E_{{{\text{inj}} . {\text{site}}}} \cdot { \exp }\left( {\eta_{i} } \right) \hfill \\ E_{\text{dose}} = \left( {\theta_{{{\text{dose0}} . 5 {\text{mg}}}} } \right)^{{{\text{dose0}} . 5 {\text{mg}}}} \hfill \\ E_{\text{weight}} = \left( {\frac{\text{weight}}{{ 8 5\;{\text{kg}}}}} \right)^{{\theta_{wt} }} \hfill \\ E_{\text{sex}} = \left( {\theta_{\text{male}} } \right)^{\text{male}} \hfill \\ E_{\text{age}}^{{}} = \left( {\theta_{\text{age65 - 74y}} } \right)^{\text{age65 - 74y}} \cdot \left( {\theta_{age \ge 75y} } \right)^{age \ge 75y} \hfill \\ E_{\text{GFR}} = \left( {\theta_{\text{GFRmild}} } \right)^{\text{GFRmild}} \cdot \left( {\theta_{\text{GFRmoderate}} } \right)^{\text{GFRmoderate}} \cdot \left( {\theta_{\text{GFRsevere}} } \right)^{\text{GFRsevere}} \hfill \\ E_{\text{race}} = \left( {\theta_{\text{BlackAfrAm}} } \right)^{\text{BlackAfrAm}} \cdot \left( {\theta_{\text{Asian}} } \right)^{\text{Asian}} \cdot \left( {\theta_{\text{Other}} } \right)^{\text{Other}} \hfill \\ E_{\text{ethnicity}} = \left( {\theta_{\text{Hispanic}} } \right)^{\text{Hispanic}} \hfill \\ E_{\text{inj,site}} = \left( {\theta_{\text{Thigh}} } \right)^{\text{Thigh}} \cdot \left( {\theta_{\text{Upperarm}} } \right)^{\text{Upperarm}} \hfill \\ \end{aligned} $$
where CL
typ was the typical semaglutide clearance (CL/
F) for the reference subject, and θ was used for covariate effect parameters. Exponents used for categorical covariate relations are indicator variables assigned the value 1 for the actual category and else 0, e.g., 1 for males and 0 for females. Groups that contained < 20 subjects were merged with the largest covariate group. Between-subject variability was assumed to be log-normally distributed and was included as
η.
Between-subject variability was estimated for CL/F and V/F in both the base and full PK models to account for the degree of variability that could be explained by inclusion of the covariates. If the dose level was missing in a subject’s dosing diary, it was assumed to be the planned dose.
Data Analysis Software
The software program R (version 2.14.2, R Foundation; Revolution Analytics, Mountain View, CA, USA, version 6) was used for data file processing, explorative data analysis, and plotting. NONMEM (ICON Development Solutions, Ellicott City, MD, USA), version 7.1.2, was used for the population pharmacokinetic analysis. Both of these programs were run as validated server installations. PsN [
29,
30] was used for the visual predictive check, and data processing was done with R.